iNCOVACC is a medicine for Covid-19, which is an Intranasal Covid Vaccine and it is the first in its type in India. iNCOVACC® is a nasal vaccine indicated for active immunization against SARS-CoV-2 virus infection.
The intranasal vaccine for iNCOVACC is a recombinant vaccination because it was made using an adenovirus vector. A tiny portion of the DNA from the bacteria or virus for which immunity is to be developed is extracted to create this type of vaccine, which is then introduced into the cells while they are being created. It is created using a stabilised pre-fusion spike protein. The vaccine has been designed to allow intranasal administration via nasal drops. The cost-effective nasal delivery device was created with low- and middle-income nations in mind.
Here are all the top benefits and side effects of iNCOVACC Vaccine.
There are millions of people who may be looking for the benefits of iNCOVACC after the arrival of BF-7 variant. As it the first covid-19 vaccine which is intranasal vaccine, which is given into the nose though a spray, and now people want to know about how it is better then previous vaccine which was given to everyone, Covishield.
Here are the top benefits of iNCOVACC:
Here are the top side effects that you may see in yourself after taking this iNCOVACC.
Here are all the top most frequently asked questions and their answer, which will help you to know more about this vaccine.
Ans. A nasal vaccine called iNCOVACC needs to be given twice, separated by four weeks (28 days). Each nostril will receive four drops, for a total of eight drops (0.5 mL dose in total).
Ans. f you experience any side effect(s), please contact/visit your health provider/ Vaccinator / Officer supervising your vaccination or immediately go to the nearest hospital. In addition, you can report side effects after vaccination to Bharat Biotech International Limited, who is the manufacturer of iNCOVACC® on a 24x7 Toll- Free Number: +1 800 102 2245 or email at pvg@bharotbiotech.com.
Ans. No, it is all your choice to have this vaccine.
Ans. As per Bharatbiotech; There is no scientific information yet available on the appropriateness of the use of iNCOVACC® along with other vaccines.
Ans. As per Bharabiotech's official website; No data exists on the use of the iNCOVACC® Vaccine in pregnant women. So we recommend avoiding this vaccine if you are pregnant, at least in the starting until some official updates don't come up for pregnant women.
Ans. Individuals who have a known severe allergy to any component of iNCOVACC® are NOT advised to be vaccinated. Each 0.5 ml of iNCOVACC® contains NLT 5x1010 particles per mL of ChAd36-SARS-CoV-S COVID-19 virus (recombinant) including excipients such as Tris (pH 7.4), Sodium Chloride, Magnesium Chloride, Glycerol, Polysorbate- 80 Individuals with a history of severe allergic reactions NOT related to vaccines or injectable medications such as environmental allergies, allergies to food, pet dander, venom, or latex- may still get vaccinated.
Individuals with a history of allergies to oral medications or a family history of allergic reactions, or who might have a mild allergy to vaccines (but no anaphylaxis) may still get vaccinated.
Ans. Individuals with HIV infection or other immunocompromised conditions, or who take immunosuppressive medications or therapies might be at increased risk for severe COVID-19. However, data is NOT currently available to establish vaccine safety and efficacy in these groups. Individuals with immunosuppression may not generate a full immune response to COVID-19. Transplant recipients should be counseled that the vaccine's effectiveness and safety profile them is not currently known.
Transplant recipients may have a weakened immune response compared to the general population. Thus, they should be advised regarding the importance of maintaining all current guidance to protect themselves even after vaccination. Immunocompromised individuals may receive COVID-19 vaccination if they have no contraindications to vaccination
Ans. No, there is no chance of getting COVID-19 post-immunization with iNCOVACC.
Ans. Let's now talk about the eligibility criteria of iNCOVACC.
There are not any eligibility for taking this vaccine, but you must be 18 years of above. If you are 18 years then you can take this vaccine.
Ans. As per Bharatbiotech, If you have the following symptoms then you should avoid this vaccine or at least mention about your condition there if you have the following.
Ans. Here are the people who should not take iNCOVACC:
Ans. Now you may be thinking about the ingredients that this vaccine used to get ready for the covid patients. As per Bhartabiotech.com, These are the ingredients that this vaccine used.
Each 0.5 ml contains NLT 5x1010 particles per mL of ChAd36-SARS-CoV-S COVID-19 virus (recombinant) including excipients such as Tris (pH 7.4), Sodium Chloride, Magnesium Chloride, Glycerol, Polysorbate- 80.
Ans. This vaccine is the first covid vaccine in India, which is given through the nose in a 2-dose series, 4 weeks apart. A total of 8 drops (0.5 mL per dose), 4 drops are administered into each nostril.
Ans. The CDSCO India has granted permission for the sale or distribution of iNCOVACC® for immunization against SARS-CoV-2 virus infection for age group ≥18 years, as per Restricted Use in Emergency Situation.
Source: All the above information is taken from the Bharatbiotech.com.